Atlas Trials

Dompé Farmaceutici S.p.A

52 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Dompé Farmaceutici S.p.A

RecordFirmDate
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (NCT07453888)Dompé Farmaceutici S.p.A2026-07-01
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED (NCT07519902)Dompé Farmaceutici S.p.A2026-06-02
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease (NCT07503886)Dompé Farmaceutici S.p.A2026-05-12
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC (NCT07395232)Dompé Farmaceutici S.p.A2025-12-01
Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye (NCT06411132)Dompé Farmaceutici S.p.A2024-05-09
Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis (NCT06411145)Dompé Farmaceutici S.p.A2024-04-26
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease. (NCT06244316)Dompé Farmaceutici S.p.A2024-01-22
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients (NCT05552261)Dompé Farmaceutici S.p.A2023-02-01
Add-on Reparixin in Adult Patients With ARDS (NCT05496868)Dompé Farmaceutici S.p.A2022-12-06
Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes. (NCT05368402)Dompé Farmaceutici S.p.A2022-09-14
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia (NCT05254990)Dompé Farmaceutici S.p.A2022-04-27
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer (NCT05212701)Dompé Farmaceutici S.p.A2022-04-19
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (NCT05136170)Dompé Farmaceutici S.p.A2022-01-27
Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study) (NCT05133180)Dompé Farmaceutici S.p.A2022-01-19
Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes (NCT05035368)Dompé Farmaceutici S.p.A2021-09-30
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia. (NCT04878055)Dompé Farmaceutici S.p.A2021-02-14
A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males (NCT04802967)Dompé Farmaceutici S.p.A2021-02-08
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients. (NCT05172050)Dompé Farmaceutici S.p.A2021-01-22
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function (NCT04628481)Dompé Farmaceutici S.p.A2021-01-12
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline. (NCT04899271)Dompé Farmaceutici S.p.A2020-12-14
A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers (NCT04854642)Dompé Farmaceutici S.p.A2020-10-20
Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis (NCT04485546)Dompé Farmaceutici S.p.A2020-09-09
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye (NCT03982368)Dompé Farmaceutici S.p.A2019-06-10
Ascending Dose Tolerability Trial and PK Assessment in Healthy Volunteers After Single & Multiple Oral Intake of DF2755A (NCT04803396)Dompé Farmaceutici S.p.A2018-11-15
A Study to Assess Efficacy and Tolerability of Ketoprofen 40 mg Granules vs Placebo (NCT03836807)Dompé Farmaceutici S.p.A2018-04-04
Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers (NCT03836859)Dompé Farmaceutici S.p.A2018-03-30

Track Dompé Farmaceutici S.p.A automatically

Every clearance here is in the API, with alerts when new ones post.